Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Plasma cell 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma 1Leukemia 1

Interventions

Dexamethasone 116Bortezomib 63Cyclophosphamide 51Lenalidomide 49Calcium Dobesilate 46Melphalan 37pomalidomide 36fludarabine 28Filgrastim 26fludarabine phosphate 23carfilzomib 22daratumumab 21Whole-Body Irradiation 17Granulocyte Colony-Stimulating Factor 17Mycophenolic Acid 15Antilymphocyte Serum 15dexamethasone acetate 14Tacrolimus 14Thalidomide 13Cyclosporine 13Busulfan 13Radiotherapy 12Peripheral Blood Stem Cell Transplantation 12ixazomib 11dexamethasone 21-phosphate 10auricularum 10pembrolizumab 9Stem Cell Transplantation 9Rituximab 9Etoposide 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × siplizumab × Plasma cell × Clear all
NCT00113646 2018-03-16

Non-Myeloablative HLA-Mismatched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies

Massachusetts General Hospital

Phase 2 Terminated
14 enrolled
LymphoidMyeloidOther hematologic neoplasmPlasma cell

Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡